CA2437639C - Long term drug delivery devices with polyurethane based polymers and their manufacture - Google Patents

Long term drug delivery devices with polyurethane based polymers and their manufacture Download PDF

Info

Publication number
CA2437639C
CA2437639C CA2437639A CA2437639A CA2437639C CA 2437639 C CA2437639 C CA 2437639C CA 2437639 A CA2437639 A CA 2437639A CA 2437639 A CA2437639 A CA 2437639A CA 2437639 C CA2437639 C CA 2437639C
Authority
CA
Canada
Prior art keywords
polyurethane
based polymer
drug delivery
active ingredients
delivery device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2437639A
Other languages
French (fr)
Other versions
CA2437639A1 (en
Inventor
Sheng-Hung Kuo
Petr Kuzma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Braeburn Pharmaceuticals Inc
Original Assignee
Braeburn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braeburn Pharmaceuticals Inc filed Critical Braeburn Pharmaceuticals Inc
Priority to CA2437639A priority Critical patent/CA2437639C/en
Priority to US10/915,625 priority patent/US7842303B2/en
Priority to ES04769233T priority patent/ES2320556T3/en
Priority to DK04769233T priority patent/DK1660034T3/en
Priority to JP2006523081A priority patent/JP5060128B2/en
Priority to DE602004019224T priority patent/DE602004019224D1/en
Priority to PL04769233T priority patent/PL1660034T3/en
Priority to PT04769233T priority patent/PT1660034E/en
Priority to MXPA06001612A priority patent/MXPA06001612A/en
Priority to CN201110053656.6A priority patent/CN102133174B/en
Priority to EP14172031.8A priority patent/EP2805709A1/en
Priority to EP08010973A priority patent/EP1982695A3/en
Priority to SI200431052T priority patent/SI1660034T1/en
Priority to CN2004800293420A priority patent/CN1863504B/en
Priority to AT04769233T priority patent/ATE421316T1/en
Priority to EP04769233A priority patent/EP1660034B1/en
Priority to PCT/IB2004/002823 priority patent/WO2005013936A2/en
Priority to AU2004262999A priority patent/AU2004262999B2/en
Publication of CA2437639A1 publication Critical patent/CA2437639A1/en
Priority to HK06113056.8A priority patent/HK1091145A1/en
Priority to HR20090209T priority patent/HRP20090209T1/en
Priority to AU2009202942A priority patent/AU2009202942B2/en
Priority to US12/873,130 priority patent/US8357389B2/en
Priority to US12/907,717 priority patent/US8343528B2/en
Priority to AU2010251786A priority patent/AU2010251786B2/en
Priority to JP2011031294A priority patent/JP5368497B2/en
Priority to HK12100714.1A priority patent/HK1160378A1/en
Priority to JP2012219869A priority patent/JP2013049678A/en
Priority to US13/693,659 priority patent/US8529936B2/en
Priority to US13/952,327 priority patent/US8658195B2/en
Priority to US14/159,119 priority patent/US20140135684A1/en
Priority to JP2014164312A priority patent/JP2014237699A/en
Application granted granted Critical
Publication of CA2437639C publication Critical patent/CA2437639C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/49—Method of mechanical manufacture
    • Y10T29/49826—Assembling or joining

Abstract

This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects, comprises: 1. a reservoir, said reservoir comprising: 2. at least one active ingredient; and 3. at least one pharmaceutically acceptable carrier; a polyurethane based polymer completely surrounding the reservoir.

Description

TITLE OF INVENTION
Long term drug delivery devices with polyurethane based polymers and their manufacture.
FIELD OF INVENTION
The present invention relates to the field of drug delivery devices and more specifically implantable drug delivery devices made of polyurethane based polymers.
BACKGROUND OF THE INVENTION
Due to its excellent biocompatibility, biostability and physical properties, polyurethane or polyurethane-containing polymers have been used to fabricate a large number of implantable devices, including pacemaker leads, artificial hearts, heart valves, stent coverings, artificial tendons, arteries and veins. See e.g., www.polymertech.com, www.cardiotech-inc.com, and www.thermedicsinc.com. Also see Hsu et al., Soc.
Biomaterials Trans., April 1998.
Known in the art is US 3,975,350 which discloses the use of polyurethanes to make implants containing pharmaceutically active agents. This patent discloses that the active agents are mixed with the polyurethane polymer prior to being cast (or shaped) into a number of forms, including tubes, rods, films, etc.
Also known is US 3,993,073 which discloses a delivery device for the controlled and continuous administration of a drug to a body site. The device disclosed therein comprises a reservoir containing a dissolved drug surrounded by a shaped wall which is insoluble in body fluid.
US 3,948,254 discloses a drug delivery device for the administration of a drug. The drug is contained within a reservoir and the device comprises pores filled with a liquid which is permeable to the passage of the drug.
- 2 -The inventors are not aware of any prior art polyurethane based drug delivery devices which can contain a drug in a solid form and which does not require a liquid medium or carrier for the diffusion of the drug at a zero order rate.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide polyurethane based long term drug delivery devices.
It is a further object of the present invention to provide biocompatible and biostable polyurethane based devices for the delivery of drugs or other compounds in a living organism.
This is accomplished through a drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects, said drug delivery device having a reservoir comprising:
a) a polyurethane based polymer completely surrounding the reservoir;
b) at least one active ingredient; and c) at least one pharmaceutically acceptable carrier;
Preferably, the drug delivery device has a cylindrically shaped reservoir.
Preferably also, the polyurethane based polymer is selected from the group consisting of: thermoplastic polyurethane, and thermoset polyurethane. Even more preferably, the thermoplastic polyurethane is made of macrodials, diisocyanates, difunctional chain extenders or mixtures thereof.
Preferably, the thermoset polyurethane is made of multifunctional polyols, isocyanates, chain extenders or mixtures thereof.
- 3 --Preferably also, the thermoset polyurethane comprises a polymer chain and cross-linking members, said thermoset polyurethane contains unsaturated bonds in the polymer chains and appropriate crosslinkers and/or initiators as cross-linking members.
Preferably, the drug delivery device is made of polyurethane which comprises functional groups selected from hydrophilic pendant groups and hydrophobic pendant groups. More preferably, the hydrophilic pendant groups are selected from ionic, carboxyl, ether, hydroxyl groups and mixtures thereof. Even more preferably, the hydrophobic pendant groups are selected from alkyl and siloxane groups and mixtures thereof.
Another object of the present invention is a process of manufacturing a drug delivery device, said process comprising:
a) precision extrusion or injection molding step to produce a hollow tube made of thermoplastic polyurethane with two open ends with desired physical dimensions;
b) sealing one of the open ends of the hollow tube;
c) loading a reservoir containing a desired formulation containing actives and carriers or filling a reservoir with pre-fabricated pellets;
d) sealing the second open end of the hollow tube; and e) conditioning and priming of the drug delivery devices to achieve the desired delivery rates for the actives.
- 4 -Preferably, the sealing steps may be carried out by using pre-fabricated plugs which are inserted on the open ends of the hollow tube with heat or solvent or by applying heat or solvent while sealing.
Yet another object of the present invention is a process of manufacturing drug delivery devices made with thermoset polyurethanes, said process comprising:
a) precision reaction injection molding or spin casting a hollow tube having two open ends;
b) curing the hollow tube;
c) sealing one end of the hollow tube;
d) loading a reservoir containing a desired formulation containing actives and carriers or filling a reservoir with pre-fabricated pellets;
e) sealing the second end of the hollow tube; and f) conditioning and priming of the drug delivery devices to achieve the desired delivery rates for the actives.
Yet another object of the present invention is a process of manufacturing drug delivery devices made with thermoset polyurethanes, said process comprising:
a) precision reaction injection molding or spin casting a hollow tube having one open end;
b) curing the hollow tube;
c) loading a reservoir containing a desired formulation containing actives and carriers or filling a reservoir with pre-fabricated pellets;
- 5 -d) sealing the open end of the hollow tube; and e) conditioning and priming of the drug delivery devices to achieve the desired delivery rates for the actives.
Another object of the present invention is a process of manufacturing drug delivery devices made with thermoset polyurethanes, wherein the production of the hollow tube and sealing of an open end, is done with an appropriate light-initiated and/or heat-initiated thermoset polyurethane formulation and initiating and curing the light-initiated and/or heat-initiated thermoset polyurethane formulation with light and/or heat.
Also another object of the present invention involves a process of manufacturing drug delivery devices made with thermoset polyurethanes, wherein the sealing of an open end, is done by inserting a pre-fabricated end plug at the open end of the hollow tube.
Yet another object of the invention is a process of manufacturing drug delivery devices made with thermoset polyurethanes, wherein the sealing of an open end, is done by inserting a pre-fabricated end plug at the open end of the hollow tube and by applying an appropriate light-initiated and/or heat-initiated thermoset polyurethane formulation on interface between the pre-fabricated end plug and the open end and initiating and curing with light and/or heat.
In one instance there is provided a drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects, said drug delivery device having a reservoir comprising:
i. at least one active ingredient;
ii. at least one pharmaceutically acceptable carrier; and
- 6 -iii. a polyurethane based polymer completely surrounding the reservoir.
Preferably the drug delivery device has a cylindrically shaped reservoir.
Preferably, the polyurethane based polymer is selected from the group comprising:
thermoplastic polyurethane, and thermoset polyurethane. More preferably, the thermoplastic polyurethane is made of macrodials, diisocyanates, &functional chain extenders or mixtures thereof. Also more preferably, the thermoset polyurethane is made of multifunctional polyols, isocyanates, chain extenders or mixtures thereof.
Even more preferably, the thermoset polyurethane comprises a polymer chain and cross-linking members, said thermoset polyurethane contains unsaturated bonds in the polymer chains and appropriate crosslinkers and/or initiators as cross-linking members.
Preferably, the polyurethane comprises functional groups selected from hydrophilic pendant groups and hydrophobic pendant groups. More preferably, the hydrophilic pendant groups are selected from ionic, carboxyl, ether, hydroxyl groups and mixtures thereof. Also preferably, the hydrophobic pendant groups are selected from alkyl, siloxane groups and mixtures thereof.
In one instance there is provided for a process of manufacturing drug delivery devices made with thermoplastic polyurethanes, said process comprising:
a) precision extrusion or injection molding step to produce a hollow tube made of thermoplastic polyurethane with two open ends with desired physical dimensions;
b) sealing one of the open ends of the hollow tube;
, _ =
- 7 -c) loading a reservoir containing a desired formulation containing actives and carriers or filling a reservoir with pre-fabricated pellets;
d) sealing the second open end of the hollow tube;
e) conditioning and priming of the drug delivery devices to achieve the desired delivery rates for the actives.
Preferably, the sealing steps may be carried out by using pre-fabricated plugs which are inserted on the open ends of the hollow tube with heat or solvent or by applying heat or solvent while sealing.
In one instance there is provided for a process of manufacturing drug delivery devices made with thermoset polyurethanes, said process comprising:
a) precision reaction injection molding or spin casting a hollow tube having two open ends;
b) curing the hollow tube;
c) sealing one end of the hollow tube;
d) loading a reservoir containing a desired formulation containing actives and carriers or filling a reservoir with pre-fabricated pellets;
e) sealing the second end of the hollow tube; and f) conditioning and priming of the drug delivery devices to achieve the desired delivery rates for the actives.
In another instance there is provided for a process of manufacturing drug delivery devices made with thermoset polyurethanes, said process comprising:
- 8 -a) precision reaction injection molding or spin casting a hollow tube having one open end;
b) curing the hollow tube;
c) loading a reservoir containing a desired formulation containing actives and carriers or filling a reservoir with pre-fabricated pellets;
d) sealing the open end of the hollow tube; and e) conditioning and priming of the drug delivery devices to achieve the desired delivery rates for the actives.
Preferably, the production of the hollow tube and the sealing of an open end are done with an appropriate light-initiated and/or heat-initiated thermoset polyurethane formulation and initiating and curing the light-initiated and/or heat-initiated thermoset polyurethane formulation with light and/or heat.
More preferably, the sealing of an open end, is done by inserting a pre-fabricated end plug at the open end of the hollow tube. Even more preferably, the sealing of an open end, is done by inserting a pre-fabricated end plug at the open end of the hollow tube and by applying an appropriate light-initiated and/or heat-initiated thermoset polyurethane formulation on interface between the pre-fabricated end plug and the open end and initiating and curing with light and/or heat.
DETAILED DESCRIPTION OF THE FIGURES
Figure 1 is a side view of an implant with two open ends as used in the present invention.
Figure 2 is a side view of the pre-fabricated end plugs used to plug the implants according to the present invention.
õ,.
- 9 -Figure 3 is a side view of an implant with one open end as used in the present invention.
Figure 4 is a graph of the elution rate of histrelin using an implant according to the present invention.
Figure 5 is a graph of the elution rate of naltrexone using an implant according to the present invention.
DETAILED DESCRIPTION OF THE INVENTION
To take the advantage of the excellent properties of polyurethane based polymers, this invention uses polyurethane based polymers as drug delivery devices for releasing drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects. The drug delivery device is preferably comprised of a cylindrically shaped reservoir surrounded by polyurethane based polymer through which controls the delivery rate of the drug inside the reservoir. The reservoir is comprised of active ingredients and other carriers. The carriers are formulated to facilitate the diffusion of the active ingredients through the polymer and to ensure the stability of the drugs inside the reservoir.
The current invention provides a drug delivery device that can achieve the following objectives: a controlled release rate (zero order release rate) to maximize therapeutic effects and minimize unwanted side effects; an easy way to retrieve the device if it is necessary to end the treatment; an increase in bioavailability with less variation in absorption and no first pass metabolism.
The release rate of the drug is governed by the Fick's Law of Diffusion as applied to a cylindrically shaped reservoir device (cartridge). The following equation describes the relationship between different parameters:
- 10 -dM 0 2 irhpA C
dt ln (ro /ri ) dM where dt drug release rate length of filled portion of device p permeability coefficient A C =
concentration gradient across the reservoir wall ro /ri ratio of outside to inside radii of device p is the permeability coefficient of the polymer used.
The permeability coefficient is primarily regulated by the hydrophilicity/hydrophobicity of the polymer, the structure of the polymer, and the interaction of drug and the polymer. Once the polymer and the active ingredient are selected, p will be a constant, h, ro, and ri are fixed and kept constant once the cylindrically shaped device is produced. A C is maintained constant by the carriers inside the reservoir.
To keep the geometry of the device as precise as possible, the preferably cylindrically shaped device can be manufactured through precision extrusion or precision molding process for thermoplastic polyurethane polymers, and reaction injection molding or spin casting process for thermosetting polyurethane polymers.
The cartridge can be made with either one end closed or both ends open. The open end can be plugged with pre-manufactured end plug to ensure a smooth end and a solid seal. The solid actives and carriers can be compressed into pellet form to maximize the loading of the actives.
To identify the location of the implant, radiopaque material can be incorporated into the delivery device by inserting it into the reservoir or by making it into end plug to be used to seal the cartridge.
- 11 -Once the cartridges are sealed on both ends with filled reservoir, they are conditioned and primed for an appropriate period of time to ensure a constant delivery rate.
The conditioning of the drug delivery devices involves the loading of the actives (drug) into the polyurethane based polymer which surrounds the reservoir. The priming is done to stop the loading of the drug into the polyurethane based polymer and thus prevent loss of the active before the actual use of the implant. The conditions used for the conditioning and priming step depend on the active, the temperature and the medium in which they are carried out. The conditions for the conditioning and priming may be the same in some instances.
The conditioning and priming step in the process of the preparation of the drug delivery devices is done to obtain a determined rate of release of a specific drug. The conditioning and priming step of the implant containing a hydrophilic drug is preferably carried out in an aqueous medium, more preferably in a saline solution. The conditioning and priming step of a drug delivery device comprising a hydrophobic drug is usually carried out in a hydrophobic medium such as an oil based medium. The conditioning and priming steps are carried out by controlling three specific factors namely the temperature, the medium and the period of time.
A person skilled in the art would understand that the conditioning and priming step of the drug delivery device will be affected by the medium in which the device is placed.
As mentioned previously, a hydrophilic drug would be preferably conditioned and primed in an aqueous solution and more preferably, in a saline solution. For example, Histrelin and Naltrexone implants have been conditioned and primed in saline solution, more specifically, conditioned in saline solution of 0.9 % sodium content and primed in saline solution of 1.8% sodium chloride content.
- 12 -The temperature used to condition and prime the drug delivery device may vary across a wide range of temperatures but, in some instances 37 C, has been preferably used.
The time period used for the conditioning and priming of the drug delivery devices may vary from a single day to several weeks depending on the release rate desired for the specific implant or drug.
A person skilled in the art will understand the steps of conditioning and priming the implants is to optimize the rate of release of the drug contained within the implant. As such, a shorter time period spent on the conditioning and the priming of a drug delivery device results in a lower rate of release of the drug compared to a similar drug delivery device which has undergone a longer conditioning and priming step.
The temperature in the conditioning and priming step will also affect the rate of release in that a lower temperature results in a lower rate of release of the drug contained in the drug delivery device when compared to a similar drug delivery device which has undergone a treatment at a higher temperature.
Similarly, in the case of aqueous solutions, which are in some cases preferably saline solutions, the sodium chloride content of the solution will also determine what type of rate of release will be obtained for the drug delivery device. More specifically, a lower content of sodium chloride would result in a higher rate of release of drug when compared to a drug delivery device which has undergone a conditioning and priming step where the sodium chloride content was higher.
The same conditions apply for hydrophobic drugs where the main difference in the conditioning and priming step would be that the conditioning and priming medium be hydrophobic medium, more specifically an oil based medium.
- 13 -The drug (actives) that can be delivered include drugs that can act on the central nervous system, psychic energizers, tranquilizers, anti-convulsants, muscle relaxants, anti-parkinson, analgesic, anti-inflammatory, anesthetic, antispasmodic, muscle contractants, anti-microbials, anti-malarials, hormonal agents, sympathomimetic, cardiovascular, diuretics, anti-parasitic and the like.
The current invention focuses on the application of polyurethane based polymers, thermoplastics or thermosets, to the creation of implantable drug devices to deliver biologically active compounds at controlled rates for prolonged period of time.
Polyurethane polymers are preferably made into cylindrical hollow tubes with one or two open ends through extrusion, (reaction) injection molding, compression molding, or spin-casting (see e.g. U. S. patents 5,266,325 and 5,292,515), depending on the type of polyurethane used.
Thermoplastic polyurethane, can be processed through extrusion, injection molding, or compression molding. Thermoset polyurethane, can be processed through reaction injection molding, compression molding, or spin-casting. The dimensions of the cylindrical hollow tube are very critical and need to be as precise as possible.
Polyurethane based polymers are synthesized from multi-functional polyols, isocyanates and chain extenders. The characteristics of each polyurethane can be attributed to its structure.
Thermoplastic polyurethanes are made of macrodials, diisocyanates, and difunctional chain extenders (e.g. U.S. patents 4,523,005 and 5,254,662). Macrodials make up the soft domains. Diisocyanates and chain extenders make up the hard domains. The hard domains serve as physical crosslinking sites for the polymers. Varying the ratio of these two domains can alter the physical characteristics of the polyurethanes.
, i^Tr
- 14 -Thermoset polyurethanes can be made of multifunctional (greater than difunctional) polyols and/or isocyanates and/or chain extenders (e.g. U.S. patents 4,386,039 and 4,131,604). Thermoset polyurethanes can also be made by introducing unsaturated bonds in the polymer chains and appropriate crosslinkers and/or initiators to do the chemical crosslinkirtg (e.g. U.S. patent 4,751,133). By controlling the amounts of crosslinking sites and how they are distributed, the release rates of the actives can be controlled.
Different functional groups can be introduced into the polyurethane polymer chains through the modification of the backbones of polyols depending on the properties desired. When the device is used for the delivery of water soluble drugs, hydrophilic pendant groups such as ionic, carboxyl, ether, and hydroxy groups are incorporated into the polyols to increase the hydrophilicity of the polymer (e.g. U. S.
patents 4,743,673 and 5,354,835). When the device is used for the delivery of hydrophobic drugs, hydrophobic pendant groups such as alkyl, siloxane groups are incorporated into the polyols to increase the hydrophobicity of the polymer (e.g. U.S. patent 6,313,254). The release rates of the actives can also be controlled by the hydrophilicity/hydrophobicity of the polyurethane polymers.
Once the appropriate polyurethane polymer is chosen, the next step is to determine the best method to fabricate the cylindrically shaped implants.
For thermoplastic polyurethanes, precision extrusion and injection molding are the preferred choices to produce two open-end hollow tubes (see Figure 1) with consistent physical dimensions. The reservoir can be loaded freely with appropriate formulations containing actives and carriers or filled with pre-fabricated pellets to maximize the loading of the actives. One open end needs to be sealed first before the loading of the formulation into the hollow tube. To seal the two open ends, two pre-fabricated end ..õ

LA LIC43/1,37 4UU3-Ub-Id
15-plugs (see Figure 2) are used. The sealing step can be accomplished through the application of heat or solvent.
For thermoset polyurethanes, precision reaction injection molding or spin casting is the preferred choice depending on the curing mechanism. Reaction injection molding is used if the curing mechanism is carried out through heat and spin casting is used if the curing mechanism is carried out through light and/or heat. Preferably, hollow tubes with one open end (see Figure 3) are made by spin casting. Preferably, hollow tubes with two open ends are made by reaction injection molding. The reservoir can be loaded in the same way as the thermoplastic polyurethanes.
Preferably, to seal an open end, an appropriate light-initiated and/or heat-initiated thermoset polyurethane formulation is used to fill the open end and this is cured with light and/or heat. More preferably, a pre-fabricated end plug can also be used to seal the open end by applying an appropriate light-initiated and/or heat-initiated thermoset polyurethane formulation on to the interface between the pre-fabricated end plug and the open end and cured it with the light and/or heat.
The final process involves the conditioning and priming of the implants to achieve the delivery rates required for the actives. Depending upon the types of active ingredient hydrophilic or hydrophobic, the appropriate conditioning and priming media will be chosen. Water based media are preferred for hydrophilic actives and oil based media are preferred for hydrophobic actives.

=
- 16 -Example 1 Tecophilic polyurethane polymer tubes are supplied by Thermedics Polymer Products and manufactured through a precision extrusion process. Tecophilic polyurethane is a family of aliphatic polyether-based thermoplastic polyurethane which can be formulated to different equilibrium water content contents of up to 150% of the weight of dry resin. Extrusion grade formulations are designed to provide maximum physical properties of thermoformed tubing or other components.
The physical data for the polymers is provided below as made available by Thermedics Polymer Product.
Tecophilic Typical Physical Test Data ii:igu4,:;; ,: j 7.A ,s._Trvx , r ,;11272.0 _1711160D-35 , ;uIP-60D-Durometer TD2240 43D 42D i 411) , 831.
: (Shore Hardness) r1 Spec Gravity 1D792 1.12 1.12 i 1.15 :
1.13 --1- ¨1 r ¨
Flex Modulus (psi) f0790 F. 4,300 4,000 I
4,000 ; 2,900 ¨

Ultimate Tensile Dry (psi) 0412 8,900 1 7,800 1 .3,300 2,200 :
. Ultimate Tensile Wet (psi) 113412 5,100 4,900 I 3,100 1,400 i ______________________________________________________________________ -I
Elongation Dry (%) F1)412 -1 430 1 450 I 500 1 1,040 Elongation Wet (%) '1-6412-1 390 7 390 1 300 , Hp-60D-20 is extruded to tubes with thickness of 0.30 mm with inside diameter of 1.75 mm. The tubes are then cut into 25 mm in length. One side of the tube is sealed with heat using a heat sealer. The sealing time is less than 1 minute. Four pellets of histrelin acetate are loaded into the tube. Each pellet weighs approximately 13.5 mg for a total of 54 mg. Each pellet is comprised of a mixture of 98% histrelin and 2% stearic acid. The second end open of the tube is sealed with heat in the same way as for the first end. The loaded implant is then conditioned and primed. The conditioning takes place at room temperature in a 0.9% saline solution for 1 day. Upon completion of the conditioning,
- 17 -the implant undergoes priming. The priming takes place at room temperatures in a 1.8% saline solution for 1 day. Each implant is tested in vitro in a medium selected to mimic the pH found in the human body. The temperature of the selected medium was kept at approximately 37.4 C during the testing. The release rates are shown on Figure 4.
Histrelin elution rates WEEKS OF ELUTION HP-60D-20 (.g/day) 1 451.733 2 582.666 3 395.9 4 310.29 5 264.92 6 247.17 7 215.93 8 201.78 9 183.22 174.99 11 167.72 12 158.37 13 153.95 14 146.46 139.83 16 129.6 17 124.46
18 118.12
19 120.35 Example 2 HP-60D-35 is extruded to tubes with thickness of 0.30 mm with inside diameter of 1.75 10 mm. The tubes are then cut into 32 mm in length. One side of the tube is sealed with heat using a heat sealer. The sealing time is less than 1 minute. Six pellets of naltrexone are loaded into the tubes and both open sides of the tubes are sealed with heat. Each pellet weighs approximately 15.0 mg for a total of 91 mg. The second end open of the tube is sealed with heat in the same way as for the first end. The loaded implant is then U4./b3 LUU3-08-16 ¨18-conditioned and primed. The conditioning takes place at room temperature in a 0.9%
saline solution for 1 week. Upon completion of the conditioning, the implant undergoes priming. The priming takes place at room temperatures in a 1.8%
saline solution for I week. Each implant is tested in vitro in a medium selected to mimic the pH found in the human body. The temperature of the selected medium was kept at approximately 37.4 C during the testing. The release rates are shown on Figure 5.
Naltrexone elution rates 0 CSIday} OSIday) {m[day) 1 1529.26 767.38 1400.95 2 151 L77 1280.03 1498.86 3 1456.01 1635.97 1449.49 4 1378.27 1607.13 1500.42 5 1393.05 1614.52 1558.37 6 1321.71 1550.39 1436.03 7 1273.07 1424.24 1300.73 8 1172.82 1246.48 1221.57 As many changes therefore may be made to the embodiments of the invention without departing from the scope thereof. It is considered that all matter contained herein be considered illustrative of the invention and not in a limiting sense.
4 "MIR

Claims (6)

We claim:
1. An implantable drug delivery device for releasing one or more active ingredients at a substantially zero order rate in vitro by diffusion through a polyurethane-based polymer for an extended period of time, said implantable drug delivery device, comprising a polyurethane-based polymer, being configured to provide a cylindrically shaped reservoir, wherein the reservoir is sealed after being charged with an effective amount of a solid formulation comprising one or more active ingredients and wherein the one or more active ingredients and the polyurethane-based polymer are selected such that both the one or more active ingredients and the polyurethane-based polymer are hydrophilic, wherein the solid formulation includes one or more pharmaceutically acceptable carriers that are not required for the substantially zero order release rate in vitro of the one or more active ingredients through the polyurethane-based polymer as governed by Fick's Law of Diffusion and wherein the polyurethane based polymer is a tecophilic polyurethane polymer.
2. The implantable drug delivery device as claimed in Claim 1, which is conditioned and primed under one or more parameters selected from a group consisting of time, temperature, and medium, and wherein the medium is selected to influence desired delivery rates of the one or more active ingredients.
3. The implantable drug delivery device as claimed in Claim 1 or 2, wherein the polyurethane comprises a hydrophilic pendant group, wherein the hydrophilic pendant group is an ionic group, a carboxyl group, an ether group, a hydroxyl group or a mixture of any two or more thereof.
4. The implantable drug delivery device as claimed in any one of Claims 1-3 in which the at least one active ingredient is a drug that can act on the central nervous system, a psychic energizer, a tranquilizer, an anti-convulsant, a muscle relaxant, an anti-parkinson, an analgesic, an anti-inflammatory, an anesthetic, an antispasmodic, a muscle contractant, or an anti-microbial.
5. An implantable drug delivery device for releasing one or more active ingredients at a substantially zero order rate in vitro by diffusion through a polyurethane-based polymer for an extended period of time to produce systemic pharmacological effects in vivo, said implantable drug delivery device comprising a polyurethane-based polymer configured to provide a cylindrically shaped reservoir, wherein the reservoir is sealed after being charged with an effective amount of a solid formulation comprising one or more active ingredients, wherein the one or more active ingredients and the polyurethane-based polymer are selected such that both the one or more active ingredients and the polyurethane-based polymer are hydrophilic and wherein the polyurethane-based polymer is a tecophilic polyurethane polymer.
6. An implantable drug delivery device for releasing one or more active ingredients at a substantially zero order rate in vitro by diffusion through a polyurethane-based polymer for an extended period of time to produce systemic pharmacological effects in vivo, said implantable drug delivery device comprising a polyurethane-based polymer configured to provide a cylindrically shaped reservoir, wherein the reservoir is sealed after being charged with an effective amount of a solid formulation comprising one or more active ingredients, and wherein the one or more active ingredients and the polyurethane-based polymer are selected such that both the one or more active ingredients and the polyurethane-based polymer are hydrophilic;
and further wherein the solid formulation includes one or more pharmaceutically acceptable carriers that are not required for the substantially zero order release rate in vitro of the one or more active ingredients through the polyurethane-based polymer as governed by Fick's Law of Diffusion and wherein the polyurethane-based polymer is a tecophilic polyurethane polymer.
CA2437639A 2003-08-11 2003-08-18 Long term drug delivery devices with polyurethane based polymers and their manufacture Expired - Fee Related CA2437639C (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
CA2437639A CA2437639C (en) 2003-08-11 2003-08-18 Long term drug delivery devices with polyurethane based polymers and their manufacture
US10/915,625 US7842303B2 (en) 2003-08-11 2004-08-10 Long term drug delivery devices with polyurethane based polymers and their manufacture
DK04769233T DK1660034T3 (en) 2003-08-11 2004-08-11 Preparation of long-term drug delivery devices of polyurethane-based polymers
JP2006523081A JP5060128B2 (en) 2003-08-11 2004-08-11 Fabrication of long-term drug delivery devices using polyurethane-based polymers
DE602004019224T DE602004019224D1 (en) 2003-08-11 2004-08-11 PREPARATION OF LONG-TERM MEDICAMENTS WITH POLYURETHANE BASED POLYMERS
AU2004262999A AU2004262999B2 (en) 2003-08-11 2004-08-11 Manufacture of long term drug delivery devices with polyurethane based polymers
PT04769233T PT1660034E (en) 2003-08-11 2004-08-11 Manufacture of long term drug delivery devices with polyurethane based polymers
MXPA06001612A MXPA06001612A (en) 2003-08-11 2004-08-11 Manufacture of long term drug delivery devices with polyurethane based polymers.
CN201110053656.6A CN102133174B (en) 2003-08-11 2004-08-11 Use the polymers manufacturing depot drug product delivery apparatus based on polyurethane
EP14172031.8A EP2805709A1 (en) 2003-08-11 2004-08-11 Manufacture of long term drug delivery devices with polyurethane
EP08010973A EP1982695A3 (en) 2003-08-11 2004-08-11 Manufacture of long term drug delivery devices with polyurethane
SI200431052T SI1660034T1 (en) 2003-08-11 2004-08-11 Manufacture of long term drug delivery devices with polyurethane based polymers
CN2004800293420A CN1863504B (en) 2003-08-11 2004-08-11 Long term drug delivery devices with polyurethane based polymers
AT04769233T ATE421316T1 (en) 2003-08-11 2004-08-11 PRODUCTION OF LONG-TERM DRUG DELIVERY DEVICES USING POLYURETHANE-BASED POLYMERS
EP04769233A EP1660034B1 (en) 2003-08-11 2004-08-11 Manufacture of long term drug delivery devices with polyurethane based polymers
PCT/IB2004/002823 WO2005013936A2 (en) 2003-08-11 2004-08-11 Manufacture of long term drug delivery devices with polyurethane based polymers
ES04769233T ES2320556T3 (en) 2003-08-11 2004-08-11 MANUFACTURE OF LONG-TERM FARMACO SUPPLY DEVICES WITH POLYURETHANE-BASED POLYMERS.
PL04769233T PL1660034T3 (en) 2003-08-11 2004-08-11 Manufacture of long term drug delivery devices with polyurethane based polymers
HK06113056.8A HK1091145A1 (en) 2003-08-11 2006-11-28 Manufacture of long term drug delivery devices with polyurethane based polymers
HR20090209T HRP20090209T1 (en) 2003-08-11 2009-04-08 Manufacture of long term drug delivery devices with polyurethane based polymers
AU2009202942A AU2009202942B2 (en) 2003-08-11 2009-07-22 Manufacture of long term drug delivery devices with polyurethane based polymers
US12/873,130 US8357389B2 (en) 2003-08-11 2010-08-31 Long term drug delivery devices with polyurethane based polymers and their manufacture
US12/907,717 US8343528B2 (en) 2003-08-11 2010-10-19 Long term drug delivery devices with polyurethane based polymers and their manufacture
AU2010251786A AU2010251786B2 (en) 2003-08-11 2010-12-14 Manufacture of long term drug delivery devices with polyurethane based polymers
JP2011031294A JP5368497B2 (en) 2003-08-11 2011-02-16 Fabrication of long-term drug delivery devices using polyurethane-based polymers
HK12100714.1A HK1160378A1 (en) 2003-08-11 2012-01-20 Manufacture of long term drug delivery devices with polyurethane based polymers
JP2012219869A JP2013049678A (en) 2003-08-11 2012-10-01 Manufacture of long term drug delivery device using polyurethane-based polymer
US13/693,659 US8529936B2 (en) 2003-08-11 2012-12-04 Long term drug delivery devices with polyurethane based polymers and their manufacture
US13/952,327 US8658195B2 (en) 2003-08-11 2013-07-26 Long term drug delivery devices with polyurethane based polymers and their manufacture
US14/159,119 US20140135684A1 (en) 2003-08-11 2014-01-20 Long term drug delivery devices with polyurethane based polymers and their manufacture
JP2014164312A JP2014237699A (en) 2003-08-11 2014-08-12 Manufacturing of long-term drug transport device using polyurethane-based polymer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49413203P 2003-08-11 2003-08-11
US60/494,132 2003-08-11
CA2437639A CA2437639C (en) 2003-08-11 2003-08-18 Long term drug delivery devices with polyurethane based polymers and their manufacture

Publications (2)

Publication Number Publication Date
CA2437639A1 CA2437639A1 (en) 2005-02-11
CA2437639C true CA2437639C (en) 2016-07-05

Family

ID=34137163

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2437639A Expired - Fee Related CA2437639C (en) 2003-08-11 2003-08-18 Long term drug delivery devices with polyurethane based polymers and their manufacture

Country Status (17)

Country Link
US (6) US7842303B2 (en)
EP (3) EP1660034B1 (en)
JP (4) JP5060128B2 (en)
CN (2) CN1863504B (en)
AT (1) ATE421316T1 (en)
AU (3) AU2004262999B2 (en)
CA (1) CA2437639C (en)
DE (1) DE602004019224D1 (en)
DK (1) DK1660034T3 (en)
ES (1) ES2320556T3 (en)
HK (2) HK1091145A1 (en)
HR (1) HRP20090209T1 (en)
MX (1) MXPA06001612A (en)
PL (1) PL1660034T3 (en)
PT (1) PT1660034E (en)
SI (1) SI1660034T1 (en)
WO (1) WO2005013936A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208540A1 (en) * 2003-08-11 2009-08-20 Indevus Pharmaceuticals, Inc. Implantable device for the delivery of naltrexone and methods of use thereof
US7858110B2 (en) * 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
CA2437639C (en) * 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
CA2570960C (en) * 2004-06-17 2013-10-01 Valera Pharmaceuticals, Inc. Compositions and methods for treating central precocious puberty
WO2006099288A2 (en) * 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US8211060B2 (en) 2005-05-10 2012-07-03 Palyon Medical (Bvi) Limited Reduced size implantable pump
US7637892B2 (en) * 2005-05-10 2009-12-29 Palyon Medical (Bvi) Limited Variable flow infusion pump system
US8915893B2 (en) 2005-05-10 2014-12-23 Palyon Medical (Bvi) Limited Variable flow infusion pump system
US8114055B2 (en) 2005-05-10 2012-02-14 Palyon Medical (Bvi) Limited Implantable pump with infinitely variable resistor
WO2008134475A2 (en) * 2007-04-27 2008-11-06 Endo Pharmaceuticals Solutions Inc., 33 Implant device release agents and methods of using same
WO2009029958A2 (en) * 2007-08-30 2009-03-05 Sunstorm Research Corporation Implantable delivery device
US9775882B2 (en) * 2007-09-20 2017-10-03 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
MY158903A (en) 2007-11-16 2016-11-30 Univ Rockefeller Antibodies specific for the protofibril form of beta-amyloid protein
JP5536053B2 (en) * 2008-06-25 2014-07-02 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． Octreotide implant with release agent
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
EP2344122A1 (en) * 2008-09-30 2011-07-20 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of octreotide and methods of use thereof
JP2012504139A (en) * 2008-09-30 2012-02-16 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． Implantable device for delivery of histrelin and method of use thereof
CA2739181C (en) * 2008-09-30 2017-03-14 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of risperidone and methods of use thereof
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
WO2011139594A2 (en) 2010-04-27 2011-11-10 Medtronic, Inc. Artificial bursa for intra-articular drug delivery
CN103889434B (en) 2011-06-21 2017-02-15 Bvw控股公司 Medical device comprising boswellic acid
MX357598B (en) * 2011-07-20 2018-07-16 F Kiser Patrick Intravaginal devices for drug delivery.
EP2771320B1 (en) 2011-10-24 2016-06-22 Endo Pharmaceuticals Inc. Cyclohexylamines
JP6149183B2 (en) * 2011-10-24 2017-06-21 ブレイバーン ファーマシューティカルズ，インコーポレイティド Implantable tizanidine composition and method of treatment thereof
US8568360B2 (en) 2011-12-28 2013-10-29 Palyon Medical (Bvi) Limited Programmable implantable pump design
CN105163794B (en) 2013-03-15 2020-03-27 塔里斯生物医药公司 Drug delivery device and method with drug permeable member
CN106029660B (en) 2013-12-16 2019-11-15 阿萨纳生物科技有限责任公司 P2X3And/or P2X2/3Compounds and methods for
EP3285850A1 (en) 2015-04-23 2018-02-28 TARIS Biomedical LLC Drug delivery devices with drug-permeable component and methods
US10172872B2 (en) 2015-07-01 2019-01-08 Region Nordjylland Aalborg Universitethospital Treatment of otitis media with retroauricular injection of an anti-inflammatory drug
CN109073649A (en) 2016-02-10 2018-12-21 新泽西鲁特格斯州立大学 The anti-LAM of novelty and anti-PIM6/LAM monoclonal antibody for the infection of diagnosing and treating mycobacterium tuberculosis
ITUA20162094A1 (en) * 2016-03-29 2017-09-29 Cid S P A IMPROVEMENT IN STENTS FOR RELEASING ACTIVE PRINCIPLES
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
EP3528813A4 (en) 2016-09-30 2020-06-03 Asana BioSciences, LLC P2x3 and/or p2x2/3 compounds and methods
WO2019094581A1 (en) * 2017-11-10 2019-05-16 Op-T Llc Methods for preventing, modulating and/or reducing cardiovascular disease
CN113164395A (en) 2018-10-15 2021-07-23 株式会社钟根堂 Long-acting naltrexone microparticle composition for injection
MX2021009957A (en) 2019-02-19 2021-11-12 Particle Sciences Inc Compartmentalized drug delivery devices.
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US20240082151A1 (en) 2019-10-07 2024-03-14 Oak Crest Institute Of Science Orally implantable drug delivery device
WO2021108722A1 (en) 2019-11-27 2021-06-03 Oak Crest Institute Of Science Sustained release drug delivery device
CN112169138A (en) * 2020-10-30 2021-01-05 苏州伟康医疗器械有限公司 End cap bonding process of catheter and catheter
US11820890B2 (en) 2021-04-01 2023-11-21 Stratasys Inc Pulverulent thermoplastic polymer blends
WO2023133517A1 (en) 2022-01-06 2023-07-13 Oak Crest Institute Of Science Subdermal implant for sustained drug delivery
CN114715483B (en) * 2022-05-04 2023-09-26 展一智能科技(东台)有限公司 Lower plugging operating mechanism and packing box finishing machine

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993073A (en) * 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3948254A (en) * 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3975350A (en) * 1972-08-02 1976-08-17 Princeton Polymer Laboratories, Incorporated Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles
US4136145A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4207890A (en) * 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4131604A (en) * 1977-11-23 1978-12-26 Thermo Electron Corporation Polyurethane elastomer for heart assist devices
US4207809A (en) 1978-03-20 1980-06-17 Restaurant Technology, Inc. Dual reservoir coffee urn
US4386039A (en) * 1980-02-11 1983-05-31 Thermo Electron Corporation Process for forming an optically clear polyurethane lens or cornea
US4523005A (en) * 1981-10-30 1985-06-11 Thermedics, Inc. Extrudable polyurethane for prosthetic devices prepared from a diisocyanate, a polytetramethylene ether polyol, and 1,4-butane diol
US4469671A (en) * 1983-02-22 1984-09-04 Eli Lilly And Company Contraceptive device
US4751133A (en) * 1984-11-13 1988-06-14 Thermedics, Inc. Medical patches and processes for producing same
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US4673565A (en) 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
JPS62223112A (en) 1986-03-25 1987-10-01 Rooto Seiyaku Kk Remedy for periodontosis
US4743673A (en) * 1986-12-19 1988-05-10 Tyndale Plains-Hunter, Ltd. Hydrophilic carboxy polyurethanes
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5207705A (en) * 1988-12-08 1993-05-04 Brigham And Women's Hospital Prosthesis of foam polyurethane and collagen and uses thereof
US5254662A (en) * 1990-09-12 1993-10-19 Polymedia Industries, Inc. Biostable polyurethane products
US5266325A (en) * 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
AU651654B2 (en) * 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
JP2530079B2 (en) * 1992-02-05 1996-09-04 ナショナル・パテント・ディベロプメント・コーポレーション Manufacture of water-swellable hydrophilic products and drug release devices
DE69320470T2 (en) * 1992-04-24 1999-04-29 Polymer Technology Group Inc COPOLYMERS AND NON-POROUS SEMI-PLEASANT MEMBRANES MADE THEREOF AND THEIR USE FOR FILTERING MOLECULES IN A PRESET MOLECULAR WEIGHT RANGE
US5629008A (en) 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5354835A (en) * 1993-07-23 1994-10-11 Saudi Basic Industries Corporation Desalination process
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
JPH10513471A (en) * 1995-02-10 1998-12-22 メドトロニック、インコーポレイテッド Methods and devices for the administration of analgesics
US5789411A (en) 1995-09-11 1998-08-04 Lance L. Gooberman P. C. Improvements to rapid opioid detoxification
RU2189221C2 (en) * 1996-02-02 2002-09-20 Элзэ Копэрейшн Method and device for administering active substance and method for treating prostate carcinoma patients
FR2752380B1 (en) * 1996-08-14 1998-10-30 Dow Corning Sa METHOD FOR MANUFACTURING A CONTROLLED RELEASE DEVICE
AUPO251096A0 (en) * 1996-09-23 1996-10-17 Cardiac Crc Nominees Pty Limited Polysiloxane-containing polyurethane elastomeric compositions
US7728049B2 (en) * 1996-10-08 2010-06-01 Zamore Alan M Irradiation conversion of thermoplastic to thermoset polymers
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US5880571A (en) 1997-09-11 1999-03-09 Sundstrand Corporation Method of and system for controlling a variable speed induction motor
DK1041975T3 (en) * 1997-12-22 2002-11-04 Alza Corp Speed-controlling membranes for controlled drug delivery devices
JP4494629B2 (en) * 1997-12-30 2010-06-30 インターシア セラピューティクス，インコーポレイティド Beneficial agent supply system with membrane plug
US20020034534A1 (en) 1999-12-16 2002-03-21 Barr Deborah P. System and method for delivering a therapeutic agent over an extended period of time in conjuction with a receptor loading dose of the therapeutic agent
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US20020028857A1 (en) * 2000-03-31 2002-03-07 Holy Norman L. Compostable, degradable plastic compositions and articles thereof
AU2001287349B2 (en) 2000-09-01 2006-03-02 Palmaya Pty Ltd Slow release pharmaceutical preparation and method of administering same
US6887270B2 (en) 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
ES2323775T3 (en) 2002-05-23 2009-07-24 Active Implants Corporation DENTAL AND ARTICULATION IMPLANTS.
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US20090208540A1 (en) * 2003-08-11 2009-08-20 Indevus Pharmaceuticals, Inc. Implantable device for the delivery of naltrexone and methods of use thereof
US7858110B2 (en) 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
WO2006078320A2 (en) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
WO2006099288A2 (en) 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
EP2094348A1 (en) 2006-11-22 2009-09-02 N.V. Organon Delivery system for a non-steroidal non-ionized hydrophilic drug
EP2101745A4 (en) 2006-12-05 2009-12-30 Landec Corp Delivery of drugs
JP5536053B2 (en) 2008-06-25 2014-07-02 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． Octreotide implant with release agent
CA2739181C (en) 2008-09-30 2017-03-14 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of risperidone and methods of use thereof
EP2344122A1 (en) 2008-09-30 2011-07-20 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of octreotide and methods of use thereof

Also Published As

Publication number Publication date
US20050037078A1 (en) 2005-02-17
AU2004262999A1 (en) 2005-02-17
HK1160378A1 (en) 2012-08-17
CN1863504B (en) 2011-05-04
SI1660034T1 (en) 2009-08-31
US20130310740A1 (en) 2013-11-21
EP1660034A2 (en) 2006-05-31
EP2805709A1 (en) 2014-11-26
US7842303B2 (en) 2010-11-30
JP2007502139A (en) 2007-02-08
EP1982695A2 (en) 2008-10-22
EP1660034B1 (en) 2009-01-21
US8357389B2 (en) 2013-01-22
WO2005013936A3 (en) 2006-04-13
PT1660034E (en) 2009-06-24
AU2009202942B2 (en) 2011-01-06
CA2437639A1 (en) 2005-02-11
HRP20090209T1 (en) 2009-06-30
EP1982695A3 (en) 2010-05-26
JP5368497B2 (en) 2013-12-18
AU2004262999B2 (en) 2009-04-23
MXPA06001612A (en) 2006-04-28
AU2010251786A1 (en) 2011-01-06
WO2005013936A2 (en) 2005-02-17
PL1660034T3 (en) 2009-07-31
US8343528B2 (en) 2013-01-01
US8658195B2 (en) 2014-02-25
ES2320556T3 (en) 2009-05-25
JP5060128B2 (en) 2012-10-31
DE602004019224D1 (en) 2009-03-12
DK1660034T3 (en) 2009-05-11
AU2010251786B2 (en) 2012-11-29
ATE421316T1 (en) 2009-02-15
CN102133174B (en) 2016-05-18
US8529936B2 (en) 2013-09-10
AU2009202942A1 (en) 2009-08-13
US20110034566A1 (en) 2011-02-10
US20110059147A1 (en) 2011-03-10
JP2014237699A (en) 2014-12-18
US20130096496A1 (en) 2013-04-18
HK1091145A1 (en) 2007-01-12
JP2013049678A (en) 2013-03-14
CN1863504A (en) 2006-11-15
US20140135684A1 (en) 2014-05-15
JP2011178782A (en) 2011-09-15
CN102133174A (en) 2011-07-27

Similar Documents

Publication Publication Date Title
CA2437639C (en) Long term drug delivery devices with polyurethane based polymers and their manufacture
US8784865B2 (en) Long term drug delivery devices with polyurethane-based polymers and their manufacture
US20090208540A1 (en) Implantable device for the delivery of naltrexone and methods of use thereof
US20130302397A1 (en) Implantable device for the delivery of histrelin and methods of use thereof
AU2013200837B2 (en) Manufacture of long term drug delivery devices with polyurethane based polymers
US20150174301A1 (en) Long term drug delivery devices with polyurethane based polymers and their manufacture

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190819